REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $31K invested in REGENERX BIOPHARMACEUTICALS in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
24% more capital invested
Capital invested by funds: $25K → $31K (+$6K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJWM
Williams Jones Wealth Management
New York
|
+$8.4K |
Top Sellers
RGN Hedge Fund Activity: Q4 2019 in Review
2 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2019, worth a combined $31K — up 24% from $25K a quarter earlier.
Fund positioning in RGN was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Williams Jones Wealth Management, adding an estimated $8.4K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $31K of REGENERX BIOPHARMACEUTICALS stock for Q4 2019, up 24% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2019 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q4 2019 was Williams Jones Wealth Management, an estimated $8.4K added.
Based on aggregated 13F filings for Q4 2019.